South San Francisco-based Theravance presented a new analysis of Phase III data for Vibativ and reported results from additional studies at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) from 10 to 13 May in…
written on 12.05.2014
ECCMID 2014: New data back Theravance's Vibativ re-launch
